Diamyd Medical AB (DMN)
XFRA XFRA Primary XMUN Summary
Diamyd Medical AB (DMN) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Diamyd Medical AB ever had a stock split?
Diamyd Medical AB Profile
| Biotechnology Industry | Healthcare Sector | Mr. Ulf Hannelius MBA, Ph.D. CEO | XFRA Exchange | SE0005162880 ISIN |
| Sweden Country | 27 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Diamyd Medical AB (publ), originally known as Diamyd Therapeutics AB, is a pioneering company in the field of precision medicine therapies aimed at autoimmune diabetes. With its headquarters in Stockholm, Sweden, the company was founded in 1984 and underwent a rebranding to its current name in April 2013. Diamyd Medical is at the forefront of developing therapies designed to treat autoimmune diabetes, using advanced immunotherapies. Their work focuses on Type 1 diabetes and Latent Autoimmune Diabetes in Adults (LADA), aiming to alter the course of these conditions through innovative treatments. The company has established a research and development collaboration with the Juvenile Diabetes Research Foundation to push forward the development of its key therapies, demonstrating its commitment to addressing autoimmune diabetes through cutting-edge scientific advancements.
Products and Services
Diamyd Medical’s portfolio centers around two innovative therapies, Diamyd and Remygen, targeting the treatment and modulation of autoimmune diabetes.
- Diamyd
An antigen-specific immunotherapy that is currently in phase III clinical trials, Diamyd represents a ground-breaking approach to treating Type 1 diabetes and Latent Autoimmune Diabetes in Adults (LADA). This therapy is designed to interact with the immune system in a highly specific manner, aiming to prevent the autoimmune response that destroys insulin-producing cells in the pancreas. By doing so, Diamyd seeks to offer a significant shift in the management and outlook of autoimmune diabetes conditions.
- Remygen
Remygen is an immunomodulation therapy that is currently being tested in phase I/II clinical trials. This therapy is not limited to Type 1 diabetes but also explores potential applications in Type 2 diabetes and LADA. Remygen is designed to regenerate insulin-producing beta cells and modulate the immune system to protect these cells from autoimmunity. This dual approach of regeneration and protection has the potential to revolutionize the treatment paradigm for diabetes, offering hope for a functional cure for the disease.
